• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

FDA Approves Taxotere(R) for the Treatment of Patients With Head and Neck Cancer

Posted on: Wednesday, 18 October 2006, 15:00 CDT

NEW YORK, October 18 /PRNewswire/ -- THIS IS A MULTIVU REPORT BROUGHT TO YOU BY SANOFI-AVENTIS.

MORE THAN FIFTY-FIVE THOUSAND AMERICANS WILL BE DIAGNOSED WITH CANCERS OF THE HEAD AND NECK THIS YEAR...AND NEARLY THIRTEEN-THOUSAND WILL DIE FROM THE DISEASE.

THE FDA HAS JUST APPROVED TAXOTERE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. A CLINICAL TRIAL DEMONSTRATED PATIENTS RECEIVING A TAXOTERE(R)-CONTAINING REGIMEN HAD A SIGNIFICANTLY LONGER TIME BEFORE THE CANCER SPREAD OF 11.4 MONTHS, COMPARED WITH 8.3 MONTHS FOR THE PATIENTS RECEIVING A STANDARD THERAPY AND EXPERIENCED SIGNIFICANTLY LONGER MEDIAN OVERALL SURVIVAL OF 18.6 MONTHS COMPARED TO 14.2 MONTHS.

DR. MARSHALL POSNER, DANA-FARBER CANCER INSTITUTE:

"For many years, patients with head and neck cancer had limited options for treatement. The FDA approval of Taxotere(R) for this disease gives patients and physicians an effective option for therapy."

THIS APPROVAL MARKS THE SEVENTH INDICATION IN THE U.S. FOR TAXOTERE. FOR MORE, LOG ONTO TAXOTERE.COM. I'M DANIELLE ADDAIR. AUDIO PROVIDED BY: sanofi-aventis

Audio: http://www.prnewswire.com/broadcast/25331/consumer.html

sanofi-aventis

CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM

Web site: http://www.taxotere.com/

Source: PRNewswire

More News in this Category